STAAR Surgical (STAA) reported a fiscal Q4 loss late Tuesday of $0.69 per diluted share, compared with earnings of $0.16 a year earlier.
Analysts polled by FactSet expected a loss of $0.18.
Net sales for the quarter that ended Dec. 27 was $49 million, down from $76.3 million a year earlier.
Analysts surveyed by FactSet expected $77.2 million.
The company expects a fiscal 2025 loss of $1.26 to $1.56 per diluted share. Analysts surveyed by FactSet expect earnings of $0.63.
In fiscal 2025, STAAR plans to manage its working capital and implement appropriate cost-cutting measures. The company intends to lower production output, decrease capital expenditures, and make targeted reductions to operating expenses, which, it said, will "impact headcount and discretionary spend."
STAAR no longer expects to achieve the Vision 2026 Target Sales and Operating Model announced on Sept. 14, 2023.
Shares of the company traded 34% lower in premarket activity Wednesday.
Price: 14.50, Change: -7.38, Percent Change: -33.73
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。